杨建良,谢群坚,刘小畅
YANG Jianliang,XIE Qunjian,LIU Xiaochang

• 1:广州市胸科医院药剂科
• 2:广东省人民医院珠海医院珠海市金湾中心医院

摘要(Abstract)：

β受体阻滞剂可减慢心率、降低心肌耗氧量、抑制肾素-血管紧张素-醛固酮系统(RAAS)、延缓心肌重构、提高左心室的射血分数(LVEF)、改善患者长期预后,是治疗心衰的基石药物。但对于心脏射血分数(EF)保留的心衰和右心衰,β受体阻滞剂的获益则尚不明确。且对植入起搏器患者的用药更应结合其自身情况分析利弊。临床药师关注医生容易忽略的药物相互作用问题,提供药学服务等,减少或避免了中毒不良事件的发生,保障安全有效的药物治疗。临床药师在临床药物治疗实践中积累药物使用和药学监护经验,并体现临床药师的价值。
Beta-blocker is the basal drug for the treatment of heart failure patients. It can reduce the heart rate and myocardial oxygen,inhibit RAAS,delay myocardial remodeling,improve LVEF and the long-term prognosis of patients. But for the right heart failure with EF reserves,the benefit of the beta-blockers was unclear. Especially in patients with implanted pacemaker that should be combined situation to analysis. Clinical pharmacists paid attention to the question of drug interactions that doctors ignored and provided pharmaceutical care for doctors. It can also be decreased or prevented incidence rate of adverse events and guarantee a safe and effective medication. The clinical pharmacists also accumulated experience in the pharmaceutical care of patients and exemplified the values of clinical pharmacists.

关键词(KeyWords)： 右心衰;房颤;β受体阻滞剂
right heart failure;atrial fibrillation;beta-blocker

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 杨建良,谢群坚,刘小畅
YANG Jianliang,XIE Qunjian,LIU Xiaochang

参考文献(References)：

• [1]Connolly S J,Kerr C R,Gent M,et al.Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes[J].N Engl J Med,2010,342(19):1385-1391.
• [2]Koh C,Hong W J,Yung T C,et al.Left ventricular torsional mechanics and diastolic function in congenital heart block with right ventricular pacing[J].Int J Cardiol,2012,160(1):31-35.
• [3]Packer M,Fowler M B,Roecker E B,et al.Effect of carvedilol on the morbidity of patients with severe chronic heart failure:results of the carvedilol prospective randomized cumulative survival(COPERNICUS)study[J].Circulation,2002,106(17):2194-2199.
• [4]Chiang C E,Wu T J,Verg K C,et al.2016 Guidelines of the Taiwan Heart Rhythm Society and the Taiwan Society of Cardiology for the management of atrial fibrillation[J/OL].Journal of the Formosan Medical Association.(2016-09-24)[2017-05-28].http://guide.medlive.cn/guideline/preview/1/12302?token=e1beb08ae66200df39881f9c819fab93.
• [5]Piotr P,Adriaan A V,Stefan D A,et al.2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure[J].Eur J Heart Fail,2016,18(8):891-975.
• [6]Nielsen J C,Lene K,Andersen H R,et al.A randomized comparison of atrial and dual-chamber pacing in 177 consecutive patients with sick sinus syndrome:Echocardiographic and clinical outcome[J].Journal of the American College of Cardiology,2003,42(4):614-623.
• [7]Nielsen J C,Thomsen P,Thuesen L.Long-term follow-up of patients from a randomised trial of atrial versus ventricular pacing for sick-sinus syndrome[J].Lancet,1997,350(9086):1210-1216.
• [8]Rich M V,Mcsherry F,Williford W O,et al.Effect of age on mortality,hospitalizations and response to digoxin in patients with heart failure:the DIG study[J].J Am Coll Cardiol,2001,38(3):806-813.
• [9]Deedwania P C,Singh B N,Ellenbegen K,et al.Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation:observation from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy(CHF-STAT)[J].Circulation,1998,98(23):2574-2579.
• [10]Kazuhiro Y,Hideki O,Masatsugu H.Effects of carvedilol on heart failure with preserved ejection fraction:the Japanese Diastolic Heat Failure Study(J-DHF)[J].Eur J Heart Fail,2013,15(1):110-118.